Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human interferon-α1b + toripalimab + anlotinib hydrochloride
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This therapeutic regimen is a triple combination therapy consisting of toripalimab, recombinant human interferon-α1b (IFN-α1b), and anlotinib hydrochloride, primarily investigated for the treatment of advanced unresectable melanoma. Toripalimab is a humanized IgG4 monoclonal antibody that functions as a checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor, thereby enhancing the immune system's ability to attack cancer cells. Anlotinib hydrochloride is a multi-targeted tyrosine kinase inhibitor (TKI) that inhibits angiogenesis and tumor proliferation by targeting vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Recombinant human interferon-α1b provides additional immunomodulatory and antiproliferative effects. This combination is being evaluated in clinical trials led by Xijing Hospital to improve response rates in patients with advanced melanoma, particularly those with mucosal or acral subtypes common in Chinese populations.
- Brand names
- TuoyiFocus V
- Other names
- Toripalimab combination therapyIFN-α1b + Toripalimab + Anlotinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IFNAR (Immune system modulation via type I interferon receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on recombinant human interferon-α1b + toripalimab + anlotinib hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human interferon-α1b + toripalimab + anlotinib hydrochloride.